Tarceva Approved, PTV News: Apr 29, 2010




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Tarceva Approved, PTV News: Apr 29, 2010
Released on: April 29, 2010. © PharmaVentures Ltd
Visitors: You are watching a 1 minute preview.
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
Roche lung cancer drug wins further EU approval
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Nigel Borshell
Senior Advisor
Nigel has over 30 years experience in Life Sciences including senior international commercial management roles in diagnostics and biotechnology gained at drug testing specialists Syva Company, Hoechst’s Behring division, US diagnostics giant Dade Behring, and as European Business Development Director for California-based Cepheid. Nigel is the author of numerous Pharmaceutical/Biotech Industry reports, papers and articles. At PharmaVentures, Nigel specialises in valuation methodologies, deal structure modelling, and pricing policies.
F. Hoffmann-La Roche
F. Hoffmann–La Roche Ltd. is a Swiss global health-care company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange.

The company headquarters are located in Basel and the company has many sites around the world - including: Nutley, NJ, Palo Alto, California, Pleasanton, Branchburg, Fishers, Indiana, Florence, South Carolina, Boulder, Colorado and Ponce, Puerto Rico in the US, Welwyn Garden City and Burgess Hill in the UK, Clarecastle in Ireland, Mannheim and Penzberg in Germany, and Shanghai in China.

The company also owns the American biotechnology company Genentech, which is a wholly owned subsidiary, and the Japanese biotechnology company Chugai Pharmaceuticals.
OSI Pharmaceuticals
OSI Pharmaceuticals is committed to “shaping medicine and changing lives” by discovering, developing and commercializing high-quality, novel and differentiated targeted medicines designed to extend life and improve the quality of life for patients with cancer and diabetes/obesity.
PharmaVentures Ltd
PharmaVentures is a company that has proven success in deals and alliances.

PharmaVentures offers:


• Over 18 years of healthcare industry experience

• Experience gained from working with in excess of 1000 clients in 38 countries, and conducting more than 450 assignments

• Over 40 specialist advisors, analysts and researchers

• Skills honed in many countries - 80% of its business comes from outside the UK